Structure-activity relationship in pyrazolo[4,3-c]pyridines, first inhibitors of PEX14-PEX5 Protein-Protein Interaction (PPI) with trypanocidal activity.

Trypanosoma protists are pathogens leading to a spectrum of devastating infectious diseases. The range of available chemotherapeutics against Trypanosoma is limited and the existing therapies are partially ineffective and cause serious adverse effects. Formation of the PEX14-PEX5 complex is essential for protein import into the parasites' glycosomes. This transport is critical for parasite metabolism and failure leads to mislocalization of glycosomal enzymes, with fatal consequences for the parasite. Hence, inhibiting the PEX14-PEX5 protein-protein interaction (PPI) is an attractive way to affect multiple metabolic pathways. Herein, we have used structure-guided computational screening and optimization to develop the first line of compounds that inhibit PEX14-PEX5 protein-protein interaction. The optimization was driven by several X-ray structures, NMR binding data and molecular dynamics simulations. Importantly, the developed compounds show significant cellular activity against Trypanosoma, including the human pathogen T. brucei gambiense and T. cruzi parasites.

[1]  E. Deeks.  Fexinidazole: First Global Approval , 2019, Drugs.

[2]  P. Biggin,et al.  BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability. , 2018, Bioorganic & medicinal chemistry.

[3]  A. Tarral,et al.  Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial , 2018, The Lancet.

[4]  I. Molina,et al.  Chagas disease , 2018, The Lancet.

[5]  Terry K. Smith,et al.  Design and Synthesis of Broad Spectrum Trypanosomatid Selective Inhibitors. , 2018, ACS infectious diseases.

[6]  M. Pollastri.  Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon. , 2017, Trends in parasitology.

[7]  Giuliano Cecchi,et al.  Human African trypanosomiasis , 2017, The Lancet.

[8]  M. Wendt,et al.  Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. , 2017, Journal of medicinal chemistry.

[9]  G. Klebe,et al.  Paying the Price of Desolvation in Solvent-Exposed Protein Pockets: Impact of Distal Solubilizing Groups on Affinity and Binding Thermodynamics in a Series of Thermolysin Inhibitors. , 2017, Journal of medicinal chemistry.

[10]  S. Magez,et al.  African Trypanosomes Undermine Humoral Responses and Vaccine Development: Link with Inflammatory Responses? , 2017, Front. Immunol..

[11]  Ian H. Gilbert,et al.  Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need , 2017, Nature Reviews Microbiology.

[12]  Vishal C. Kalel,et al.  Inhibitors of PEX14 disrupt protein import into glycosomes and kill Trypanosoma parasites , 2017, Science.

[13]  D. Molyneux,et al.  Neglected tropical diseases: progress towards addressing the chronic pandemic , 2017, The Lancet.

[14]  M. Barrett,et al.  The animal trypanosomiases and their chemotherapy: a review , 2016, Parasitology.

[15]  Ana Rodriguez,et al.  Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides. , 2016, Journal of medicinal chemistry.

[16]  Glen Spraggon,et al.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness , 2016, Nature.

[17]  P. Michels,et al.  Biogenesis, maintenance and dynamics of glycosomes in trypanosomatid parasites. , 2016, Biochimica et biophysica acta.

[18]  D. Scott,et al.  Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.

[19]  M. Mizuguchi,et al.  Characterization of the interaction between Trypanosoma brucei Pex5p and its receptor Pex14p , 2016, FEBS letters.

[20]  M. Berriman,et al.  Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei , 2015, The Journal of antimicrobial chemotherapy.

[21]  C. Riera,et al.  Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity , 2015, European journal of medicinal chemistry.

[22]  D. Bernard,et al.  Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.

[23]  Daqing Sun,et al.  Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. , 2014, Journal of medicinal chemistry.

[24]  Gert Vriend,et al.  YASARA View—molecular graphics for all devices—from smartphones to workstations , 2014, Bioinform..

[25]  S. Wyllie,et al.  Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects , 2014, Trends in parasitology.

[26]  P. Michels,et al.  Glycosomal targets for anti-trypanosomatid drug discovery. , 2014, Current medicinal chemistry.

[27]  T. Madl,et al.  A Novel Pex14 Protein-interacting Site of Human Pex5 Is Critical for Matrix Protein Import into Peroxisomes*♦ , 2013, The Journal of Biological Chemistry.

[28]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[29]  P. Kennedy.  Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness) , 2013, The Lancet Neurology.

[30]  P. Michels,et al.  Translocation of solutes and proteins across the glycosomal membrane of trypanosomes; possibilities and limitations for targeting with trypanocidal drugs , 2012, Parasitology.

[31]  Jan H. Jensen,et al.  Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values. , 2011, Journal of chemical theory and computation.

[32]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[33]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[34]  S. Magez,et al.  Current status of vaccination against African trypanosomiasis , 2010, Parasitology.

[35]  K. Read,et al.  Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis , 2010, Antimicrobial Agents and Chemotherapy.

[36]  J. A. Suárez,et al.  Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. , 2010, The Journal of infectious diseases.

[37]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[38]  W. Kabsch.  XDS , 2010, Acta crystallographica. Section D, Biological crystallography.

[39]  M. Wilmanns,et al.  Structural basis for competitive interactions of Pex14 with the import receptors Pex5 and Pex19 , 2009, The EMBO journal.

[40]  Jianrui Su,et al.  Crystal structure of the conserved N-terminal domain of the peroxisomal matrix protein import receptor, Pex14p , 2008, Proceedings of the National Academy of Sciences.

[41]  Barbara M. Bakker,et al.  Compartmentation prevents a lethal turbo-explosion of glycolysis in trypanosomes , 2008, Proceedings of the National Academy of Sciences.

[42]  Simon Croft,et al.  Kinetoplastids: related protozoan pathogens, different diseases. , 2008, The Journal of clinical investigation.

[43]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[44]  C. Mioskowski,et al.  A convenient aminolysis of esters catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) under solvent-free conditions , 2007 .

[45]  Federico D. Sacerdoti,et al.  Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters , 2006, ACM/IEEE SC 2006 Conference (SC'06).

[46]  Ji-tai Li,et al.  Efficient and Practical Synthesis of Mannich Bases Related to Gramine Mediated by Zinc Chloride , 2006 .

[47]  Daniel Nilsson,et al.  Comparative Genomics of Trypanosomatid Parasitic Protozoa , 2005, Science.

[48]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[49]  Marilyn Parsons,et al.  Probing the Role of Compartmentation of Glycolysis in Procyclic Form Trypanosoma brucei , 2005, Journal of Biological Chemistry.

[50]  Bernhard Rupp,et al.  Matthews coefficient probabilities: Improved estimates for unit cell contents of proteins, DNA, and protein–nucleic acid complex crystals , 2003, Protein science : a publication of the Protein Society.

[51]  W. Hol,et al.  Characterization of Trypanosoma brucei PEX14 and its role in the import of glycosomal matrix proteins. , 2003, European journal of biochemistry.

[52]  Marilyn Parsons,et al.  Glucose is toxic to glycosome-deficient trypanosomes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Kaminsky,et al.  The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. , 1997, Acta tropica.

[54]  F. Buckner,et al.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase , 1996, Antimicrobial agents and chemotherapy.

[55]  J. Koella,et al.  A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. , 1993, Acta tropica.

[56]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[57]  H Hirumi,et al.  Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. , 1989, The Journal of parasitology.

[58]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.

[59]  William L. Jorgensen,et al.  Temperature and size dependence for Monte Carlo simulations of TIP4P water , 1985 .

[60]  T. Baltz,et al.  Cultivation in a semi‐defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. , 1985, The EMBO journal.

[61]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[62]  Anton Simeonov,et al.  AlphaScreen-Based Assays: Ultra-High-Throughput Screening for Small-Molecule Inhibitors of Challenging Enzymes and Protein-Protein Interactions. , 2016, Methods in molecular biology.

[63]  M. Soares,et al.  Selection of molecular targets for drug development against trypanosomatids. , 2014, Sub-cellular biochemistry.

[64]  W. Schliebs.  Sleeping sickness: PEX and drugs. , 2006, Biochimica et biophysica acta.

[65]  Richard J Morris,et al.  ARP/wARP and automatic interpretation of protein electron density maps. , 2003, Methods in enzymology.